New lung device aims to calm COPD symptoms
NCT ID NCT07361653
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a device that targets nerves in the lungs to help people with moderate to severe COPD breathe easier. About 300 participants will be randomly assigned to receive the real treatment or a sham procedure. Researchers will track symptoms, exercise ability, and flare-ups over time to see if the device is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Targeted Lung Denervation (TLD) Catheter
- What this could lead to
- If it works, this could offer a new way to reduce COPD symptoms and flare-ups without daily medication.
- What could go wrong
- This is a pivotal study, but the treatment is still experimental. It may not improve symptoms, and there are risks from the bronchoscopy procedure, such as bleeding or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Symptomatic chronic obstructive pulmonary disease * History of COPD exacerbation(s) * Stable medical therapy * Candidate for bronchoscopy Exclusion Criteria: * Prior lung intervention with device in place * Using tobacco products, e-cigarettes, vape or other inhaled non-pharmacological substance * Clinically significant serious or unstable medical conditions (e.g., heart disease requiring treatment, uncontrolled diabetes) * Pregnant, nursing, or intent to become pregnant during study duration
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own airway stem cells repair damaged lungs in COPD?
- Can Device-Preserved donor lungs boost transplant success?
- Tiny One-Way valves for emphysema under close watch in japan
- Six biologics put to the test in Real-World asthma and COPD care
- Is RSV a hidden driver of severe COPD attacks?
- Can a breathing routine ease COPD breathlessness?